Achieve Life Sciences Inc (ACHV) reported its Q1 2026 earnings with an earnings per share (EPS) of -0.19, significantly better than the forecast of -0.43, marking a 55.81% surprise. Following this announcement, the stock surged 6.62% to $5.96 in pre-market trading, although it saw a slight decline of 1.01% in aftermarket trading. This positive performance is attributed to the company's robust financial position, bolstered by a recent capital raise of $180 million, and promising results from clinical trials of its cytisinicline program aimed at smoking cessation.

The company is advancing its cytisinicline program, which targets the underserved smoking and vaping cessation markets. Achieve Life Sciences plans to resubmit its New Drug Application (NDA) in Q4 2026, with a commercial launch anticipated in the first half of 2027. CEO Dr. Andrew Goldberg emphasized the importance of the recent capital raise for executing the company's broader commercial strategy. However, challenges remain, including regulatory delays and competition in the smoking cessation market. Analysts raised questions during the earnings call about manufacturing transitions and regulatory timelines, which management addressed by highlighting their partnership with Adare Pharma Solutions for manufacturing readiness.